As for the incidence of grade 3 or higher hematological and non-hematological adverse events, the MAbs targeting CD38 group was associated with a higher incidence of neutropenia and a similar incidence of anemia, thrombocytopenia, lymphopenia, pneumonia, and diarrhea compared with the MAbs targeting SLAMF7 group. This evidence concerns the gene CD38 and Decreased total neutrophil count.